Key facts
- Invizius’s last known valuation is $47.8M (Jun 2026).
- It has raised $18.7M; the latest was Later Stage VC ($13.4M) in Jun 2026.
- Notable investors include Innovate UK, Scottish Enterprise, SyndicateRoom, Mercia Ventures, Meltwind Advisory — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Invizius
- ·The full record, as it builds
Funding rounds
No funding rounds for Invizius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Invizius
Developer of a complementary-regulating therapy platform designed to mitigate harmful immune responses in extracorporeal medical procedures. The company offers a novel priming protein that coats dialysis circuits, suppresses complement activation, and preserves infection control for reducing mortality and morbidity, enabling clinicians treating patients on dialysis and other extracorporeal support to reduce inflammation-related complications and improve patient safety.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2018
- Employees
- 10
- Website
- invizius.com/
- Ownership
- Privately Held (backing)
Invizius doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Invizius shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Invizius in its N-PORT filings yet. We sweep new filings monthly.